Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
September 5, 2025Current Medicinal Chemistry

"Next-in-class" GLP-1R Danuglipron- and Lotiglipron-like Agonists: A Patent Review (2020-2024)

View Full Paper
Ask AI
Bookmark
Share

Authors

ETE. TolkachevaASAlexandr Yu. SalievTSTagir L. Salakhov

Discussion

Loading...

Member takes

Overview

This review identifies structural trends of 'next-in-class' GLP-1 receptor agonists for type 2 diabetes, suggesting potential new therapies.

Key Points

  • The analysis points to key general structure-activity relationship (SAR) trends in GLP-1 receptor agonists.
  • Over 5,000 compounds were examined from 67 patent publications, highlighting diverse chemical approaches.
  • The presence of a carboxyl group appears to enhance agonist activity, while bioisosteric analogs may improve the ADME profile.
  • Despite limited clinical success for danuglipron and lotiglipron, promising new chemotypes are emerging for potential future approvals.

Cite This Study

Tolkacheva et al. (2025) studied this question.

synapsesocial.com/papers/68c23922b210217d6477a281https://doi.org/10.2174/0109298673366258250710101146
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Novel GLP-1-Based Medications for Type 2 Diabetes and Obesity2025 · 31 citations
  2. 2Structural basis for chemotype diversity in small molecule GLP-1 receptor agonist drug discovery2025
  3. 3In Silico discovery and design of molecular glues as a new strategy for development of non-peptidic, small-molecule agonists of GLP-1 receptor2025
  4. 4An Insight into Pharmaceutical Design and Pharmacokinetic Characteristics of GLP-1 RAs2025 · 5 citations
  5. 5GLP-1 receptor agonism: a transformative approach for managing type-2 diabetes and obesity2025 · 17 citations